The DIO1 Knockout HAP1 Polyclonal Cells product consists of a pool of CRISPR/Cas9-edited polyclonal knockout cells, representing a heterogeneous population carrying targeted disruptions in the DIO1 gene. This format is ideal for functional genomics studies requiring a loss-of-function model without the clonal selection biases inherent in single-cell-derived cell lines. The polyclonal pool preserves genetic diversity while ensuring robust knockout coverage across the population, making it suitable for high-throughput screening and phenotype characterization.
These knockout cells are engineered in the HAP1 cell line, a near-haploid human fibroblastoid line originally derived from the KBM-7 chronic myeloid leukemia background. HAP1 cells are adherent and possess a predominantly haploid karyotype, which simplifies gene editing by removing the need for biallelic inactivation. This genetic simplicity enables efficient generation of polyclonal knockouts and facilitates clear genotype-phenotype correlations. The cell line is widely adopted for CRISPR-based screens, drug target validation, and pathway dissection in cellular models of human disease.
DIO1 encodes type I iodothyronine deiodinase, a selenoenzyme that catalyzes the outer ring deiodination of thyroxine (T4) to produce biologically active triiodothyronine (T3). This reaction occurs primarily in the liver and kidney, thereby regulating systemic thyroid hormone availability and metabolic homeostasis. The enzymatic activity of DIO1 is influenced by upstream regulators such as thyroid hormone (T3), selenium, and inflammatory cytokines IL-6 and TNF-alpha. DIO1-dependent T3 production feeds into downstream targets including T3-responsive gene expression programs that govern lipogenesis and metabolic regulation. The enzyme interacts with selenoprotein biogenesis factors and thiol cofactors to maintain its catalytic function. Within the broader thyroid hormone signaling network, DIO1 functions alongside deiodinase isoforms DIO2 and DIO3, thyroid hormone receptors THRA and THRB, and membrane transporters SLC16A2 and SLC7A5, collectively modulating the cellular and systemic actions of thyroid hormones.
In the HAP1 near-haploid context, disruption of DIO1 provides a clean genetic background to dissect thyroid hormone metabolism without interference from a second intact allele. This model is particularly valuable for studying the intracellular regulation of T4-to-T3 conversion and the downstream metabolic consequences, including effects on lipid metabolism and energy homeostasis. Because HAP1 cells express components of the thyroid hormone signaling machinery, the knockout permits systematic analysis of DIO1??s contribution to hormone processing in a simplified chromosomal setting. Researchers can therefore distinguish direct effects of T3 production from compensatory responses mediated by other deiodinase family members.
Applications of the DIO1 Knockout HAP1 Polyclonal Cells include investigating the fundamental biochemistry of deiodination, developing and testing pharmacological modulators of thyroid hormone signaling for thyroid disorders or non-thyroidal illness syndrome, and exploring the intersection between selenium metabolism and hormone bioactivation. Key experimental readouts include deiodinase activity assays to measure T4-to-T3 conversion, RT-qPCR and western blotting for gene and protein expression analysis, and T4/T3 quantification by mass spectrometry or immunoassay. Transcriptomic approaches such as RNA-seq can further uncover global gene regulatory changes due to DIO1 loss. The polyclonal format is especially suitable for screening contexts where population-level responses are desired. For further information or to discuss custom applications, please contact Ascent Research.
